Sapna Patel, MD
Medical Oncology · Aurora, CONPI 1992842280
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Merck accounts for 66.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $86,104 and has fallen 68.3% since, to $27,317 in 2025. Among medical oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $1163.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$123K
- E.r. Squibb & Sons, L.L.C.$18K
- Novartis$11K
- Sun Pharmaceutical Industries Inc.$9K
- Array Biopharma Inc$8K
- Hexal AG$7K
- plus $9K from 9 others
Across 26 payments — averaging $29,958 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$326K
- Seagen Inc.$192K
- Clinigen, Inc.$133K
- Pfizer$74K
- Array Biopharma Inc$29K
- Merck$23K
What the payments were for
- Consulting fees$86,23146%
- Speaking & faculty fees$43,84524%
- Travel & lodging$51,47728%
- Food & beverage$4,5832%
- Gifts$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 85 | $123,233 |
| E.r. Squibb & Sons, L.L.C. | 16 | $18,058 |
| Novartis | 4 | $11,300 |
| Sun Pharmaceutical Industries Inc. | 7 | $9,128 |
| Array Biopharma Inc | 8 | $7,900 |
| Hexal AG | 1 | $7,425 |
| Trisalus Life Sciences, Inc. | 27 | $4,749 |
| Daiichi Sankyo Inc. | 2 | $2,079 |
| Pfizer | 2 | $1,957 |
| Iovance Biotherapeutics, Inc. | 1 | $137 |
| Regeneron Healthcare Solutions, Inc. | 1 | $68 |
| Mannkind Corporation | 3 | $65 |
| Lilly USA, LLC | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $24 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$186,165 in reported general payments places this provider in the 95th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Aurora
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
- Erin SchenkAurora$63K
- Karl LewisAurora$62K
- Jose PachecoAurora$50K
- Leonard GlodeAurora$49K
- Robert DoebeleAurora$38K
- Christopher LieuAurora$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.